European Companies Search Engine
EU funding (€3,787,933): in vivo optogeneticS, elecTrophysiology and phArmacology with an ultRasonically-powered DUST for Parkinson's Disease Hor 28 Aug 2017 EU Research and Innovation programme "Horizon"
Overview
Text
in vivo optogeneticS, elecTrophysiology and phArmacology with an ultRasonically-powered DUST for Parkinson's Disease
The main goal of the STARDUST project is to realize a novel wireless implantable and independent micro-scale device (200x200x200 µm3) enabling in-vivo electrophysiology, optogenetics and ultra-localized drug delivery in freely moving animals. The device will be used to target specific neural circuits of the brain and test a new therapeutic approach for Parkinson’s Disease (PD). The methods used in this project are based on cutting-edge miniaturized technology combining integrated chips, microelectromechanical systems (MEMS), local drug delivery, integrated electrodes and micro-scale light emitting diodes (µLEDs). STARDUST will benefit from these advances and for the first time provide an implantable ultrasonically-powered miniaturized device for in-vivo optogenetics, local drug delivery and electrophysiological monitoring – all in one single device. The proposed device is expected to provide an output power of 1-20 mW/mm2 for optogenetics with two different wavelengths, one for neuron activation and one for triggering drug-delivery; STARDUST will provide proof of concept. The main novelty of the STARDUST project is the convergence of multiple, interdisciplinary fields including optogenetics, triggered drug-delivery, miniaturized ultrasonic energy harvesting, material science and nanoelectronics. The main ambition of the project is to develop a new technology platform to be used for future implantable in-vivo optogenetic devices for monitoring and treating diseases, with an optional local drug delivery add-on beyond 2025. Establishing proof of concept of the STARDUST platform will be the foundation for other applications within photodynamic therapy such as cancer treatment and other neurological and non-neurological disorders.
Funded Companies:
| Company name | Funding amount |
| Aarhus Universitet | €1,072,789 |
| Biomodics ApS | €485,736 |
| Centre National de la Recherche Scientifique CNRS | €592,855 |
| Fraunhofer Gesellschaft ZUR Forderung DER Angewandten Forschung e. V. | €375,121 |
| Humboldt-Universitaet ZU Berlin | €356,000 |
| Spinverse AB | €0.00 |
| Spinverse Oy | €171,623 |
| Universidade Federal do Pará | €60,500 |
| University College Cork - National University of Ireland, Cork | €360,514 |
| VIB VZW | €312,794 |
Source: https://cordis.europa.eu/project/id/767092
The filing refers to a past date, and does not necessarily reflect the current state.